Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 3:00 p.m. ET. Interested parties can access the live webcast through the Investors section of www.acumenpharm.com, where it will remain available for 90 days. The company specializes in developing novel therapeutics targeting toxic soluble amyloid beta oligomers.
Acumen Pharmaceuticals (NASDAQ: ABOS), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti per la malattia di Alzheimer, ha annunciato la sua partecipazione al 7° Annual Evercore ISI HealthCONx Conference. Il management dell'azienda parteciperà a una conversazione informale martedì 3 dicembre 2024, alle 15:00 ET. Le parti interessate possono accedere alla diretta web attraverso la sezione Investitori di www.acumenpharm.com, dove rimarrà disponibile per 90 giorni. L'azienda è specializzata nello sviluppo di nuove terapie mirate agli oligomeri tossici solubili di beta-amiloide.
Acumen Pharmaceuticals (NASDAQ: ABOS), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de tratamientos para la enfermedad de Alzheimer, ha anunciado su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. La dirección de la empresa participará en una charla informal el martes 3 de diciembre de 2024, a las 3:00 p.m. ET. Las partes interesadas pueden acceder a la transmisión web en vivo a través de la sección para Inversores de www.acumenpharm.com, donde permanecerá disponible durante 90 días. La empresa se especializa en el desarrollo de nuevos tratamientos que apuntan a los oligómeros tóxicos solubles de beta-amiloide.
Acumen Pharmaceuticals (NASDAQ: ABOS), 알츠하이머병 치료제를 개발하는데 집중하는 임상 단계의 생명공학 회사가 제7회 연례 Evercore ISI HealthCONx 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 12월 3일 화요일 오후 3시(ET)에 화상 대화에 참여할 예정입니다. 관심 있는 분들은 www.acumenpharm.com의 투자자 섹션을 통해 생중계를 통해 접속할 수 있으며, 해당 내용은 90일 동안 이용 가능합니다. 이 회사는 독성 가용성 아밀로이드 베타 올리고머를 표적으로 하는 새로운 치료제 개발에 전문화되어 있습니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une société biopharmaceutique en phase clinique axée sur le développement de traitements pour la maladie d'Alzheimer, a annoncé sa participation à la 7ème Conférence Annuelle Evercore ISI HealthCONx. La direction de l'entreprise participera à une discussion informelle le mardi 3 décembre 2024, à 15h00 ET. Les parties intéressées peuvent accéder à la retransmission en direct via la section Investisseurs de www.acumenpharm.com, où elle restera disponible pendant 90 jours. L'entreprise se spécialise dans le développement de nouvelles thérapies ciblant les oligomères bêta-amyloïdes solubles toxiques.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Behandlungen für Alzheimer-Krankheit konzentriert, hat seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 3. Dezember 2024, um 15:00 Uhr ET an einem Gespräch teilnehmen. Interessierte können den Livestream über den Bereich Investoren auf www.acumenpharm.com abrufen, wo er 90 Tage lang verfügbar bleibt. Das Unternehmen hat sich auf die Entwicklung neuartiger Therapeutika spezialisiert, die auf toxische lösliche Beta-Amyloid-Oligomere abzielen.
- None.
- None.
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) presenting at the Evercore ISI HealthCONx Conference 2024?
How long will Acumen Pharmaceuticals' (ABOS) HealthCONx Conference webcast be available?
What type of Alzheimer's treatment is Acumen Pharmaceuticals (ABOS) developing?
Where can investors watch Acumen Pharmaceuticals' (ABOS) HealthCONx Conference presentation?
